Af­ter FTC scruti­ny of Sanofi deal, Maze finds a new Pompe part­ner in Sh­iono­gi

Maze Ther­a­peu­tics has found a new buy­er for its Pompe dis­ease can­di­date, five months af­ter scruti­ny from the Fed­er­al Trade Com­mis­sion led Sanofi to back out of a deal for the clin­i­cal-stage drug.

The new li­censee is Sh­iono­gi, the com­pa­nies said Fri­day morn­ing. The Os­a­ka, Japan-based phar­ma will dish out $150 mil­lion up­front and pay an undis­closed amount in biobucks. Al­most a year ago to the day, Maze dis­closed that Sanofi would dole out the same amount up­front for the oral can­di­date and could pay an­oth­er $600 mil­lion in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER